Clinical and Laboratory Features of Covid - 19 Course in Combination with Pneumonia
Keywords:
COVID - 19, SARS-CoV-2, СOVID 19 - associated pneumoniaAbstract
Relevance. The first outbreak of COVID-19 was recorded in December 2019, in Wuhan, China. Four months after the outbreak, WHO announced the COVID-19 pandemic (March 11, 2020), which indicates the high contagiousness of this infection. The entrance gates of the pathogen are the epithelium of the upper respiratory tract, epithelial cells of the stomach and intestines. The initial stage of infection is the penetration of SARS-CoV-2 into target cells that have type II angiotensin-converting enzyme receptors(ACE2 — аngiotensin-converting en¬zyme 2). The novel human corona virus can cause a range of diseases, from mild acute respiratory infections to severe acute respiratory syndrome (SARS). Extra pulmonary manifestations include: bleeding disorder, myocardial dysfunction and arrhythmia, acute coronary syndrome, acute renal failure, gastrointestinal disorders, hepatocellular damage, hyperglycemia and ketosis, neurological diseases, eye symptoms and dermatological complications.
Materials and research methods. The data of examination and treatment of 102 patients with moderate severity of the course of COVID-19 were analyzed. Treated from July to August 2020 in a specialized hospital formed for the treatment of patients with COVID-19, the Bukhara State Medical Institute in the dormitory of the Bukhara Technological Institute. When assessing the condition and method of treatment, we were guided by temporary recommendations for the management of patients infected with COVID-19 - No. 7 approved by the Ministry of Health of the Republic of Uzbekistan dated 15. 08. According to the protocol, patients with COVID - 19, depending on the severity of the disease, are divided into 4 groups. The protocol contains specific recommendations on the scope of examination and treatment, taking into account the severity of the patient's condition.
Conclusions. When assessing the condition of patients with COVID - 19 associated pneumonia, indicators of intoxication, blood coagulation and SpO2% of blood are important. The main criteria for assessing the state of the coagulogram in COVID-19 are: D-dimer; PT; Platelets; Fibrinogen blood.
References
Radiation diagnosis of corona virus disease (COVID-19): organization, methodology, interpretation of results: Preprint No. TsDT - 2020 - II. Version 2 dated 04/17/2020 / Comp. S. P. Morozov, D. N. Protsenko, S. V. Smetanina [et al.] // Series "Best practices of radiological and instrumental diagnostics". - Issue 65. - M., 2020. - 78 p.
Xiao L., Sakagami H., and Miwa N. ACE2: The key molecule for un¬derstanding the path physiology of severe and critical conditions of COVID-19: Demon or Angel? Viruses. 2020 Apr 28; 12(5): 491. https://doi. Org/10. 3390/v12050491 PMID: 32354022
Guan, W. J. et al. Clinical characteristics of corona virus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
Anticoagulant treatment is associated with decreased mortality in severe corona virus disease 2019 patients with coagulopathy. Tang N and other/PMID: 32220112 DOI: 10. 1111/jth. 14817.
Thrombocytopenia is associated with severe corona virus disease 2019 (COVID 19) infections: A meta-analysis Lippi G and other/ DOI: 10. 1016/j. cca. 2020. 03. 022
Galstyan G. M. Coagulopathy in COVID-19. Pulmonology. 2020; 30 (5): 645–657. DOI: 10. 18093/0869-0189-2020-30-5-645-657
Safoev B. B. , Boltaev T. SH. , Latipov O. Z. Results of development of a new treatment method patients with panarizations // Annals of the Romanian Society for Cell Biology. – 2021, Vol. 25, Issue 4, 2021, Pages. 1838 – 1846.
